| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLRC1 |
| Uniprot No | P26715 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 100-233aa |
| 氨基酸序列 | HHHHHHHHRHNNSSLNTRTQKARHCGHCPEEWITYSNSCYYIGKERRTWE ESLLACTSKNSSLLSIDNEEEMKFLSIISPSSWIGVFRNSSHHPWVTMNG LAFKHEIKDSDNAELNCAVLQVNRLKSAQC GSSIIYHCKHKL |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLRC1重组蛋白的3篇参考文献示例(内容基于公开研究整理，部分为虚构示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Structural and Functional Characterization of Recombinant KLRC1 (NKG2A) Protein*
**作者**：Smith A, et al.
**摘要**：本研究通过哺乳动物表达系统成功表达并纯化重组KLRC1蛋白，结合X射线晶体学解析其与HLA-E配体的复合物结构，揭示了NKG2A与HLA-E结合的分子机制，为免疫调节治疗提供结构基础。
2. **文献名称**：*Recombinant KLRC1 Inhibits NK Cell Cytotoxicity via Interaction with HLA-E*
**作者**：Jones B, et al.
**摘要**：利用重组KLRC1蛋白进行体外功能实验，证明其通过结合靶细胞表面HLA-E分子抑制自然杀伤细胞(NK细胞)的杀伤活性，验证了KLRC1在免疫检查点中的抑制作用。
3. **文献名称**：*Engineering Soluble KLRC1 Protein for Cancer Immunotherapy Screening*
**作者**：Wang C, et al.
**摘要**：开发了一种可溶性重组KLRC1蛋白，用于高通量筛选阻断NKG2A-HLA-E相互作用的抗体或小分子，评估其在增强抗肿瘤免疫应答中的潜在治疗价值。
---
**说明**：以上文献为示例性质，实际研究中需通过PubMed、Web of Science等平台检索具体文章。建议使用关键词“KLRC1 recombinant protein”“NKG2A expression”或结合研究领域(如“cancer immunotherapy”“structural biology”)进一步筛选。
KLRC1. also known as Killer cell lectin-like receptor subfamily C member 1. encodes the NKG2A protein, a critical inhibitory receptor expressed on natural killer (NK) cells and a subset of T cells. Functioning as a heterodimer with CD94. NKG2A recognizes the non-classical MHC class I molecule HLA-E, which presents peptides derived from classical MHC I leader sequences. This interaction delivers inhibitory signals to immune cells, balancing cytotoxicity and preventing autoimmune damage while maintaining surveillance against infected or malignant cells. Dysregulation of NKG2A is implicated in immune evasion by tumors and chronic viral infections, making it a focal point in immunotherapeutic research.
Recombinant KLRC1 protein is engineered to study the structural and functional aspects of NKG2A. Produced using expression systems like mammalian cells (e.g., HEK293 or CHO), the recombinant protein often includes extracellular domains critical for ligand binding, sometimes fused with tags (e.g., Fc or His) for purification and detection. Its production enables in vitro exploration of receptor-ligand interactions, signal transduction mechanisms, and competitive inhibition assays.
In therapeutic contexts, KLRC1 recombinant protein aids in developing checkpoint inhibitors. Monoclonal antibodies targeting NKG2A (e.g., Monalizumab) aim to block its inhibitory function, enhancing NK/T cell-mediated tumor clearance. Additionally, it serves as a tool to investigate viral immune evasion strategies, as pathogens like HIV and cytomegalovirus exploit HLA-E/NKG2A interactions to suppress immunity. Beyond oncology, recombinant KLRC1 contributes to understanding autoimmune diseases and transplantation tolerance. Its versatility in basic research and drug development underscores its significance in advancing immune-targeted therapies.
×
